Technology evaluation: IMC-1C11, ImClone Systems.

Abstract

ImClone is developing IMC-IC11, an anti-angiogenesis chimeric monoclonal antibody specific vascular endothelial growth factor receptor 2 (VEGFR-2, also known Flk-1 in mice), for the potential treatment of cancer [156625]; it in phase I trials for the treatment of colorectal carcinoma [379143]. The related antibody DC-101 provided proof-of-principle that an anti-VEGF receptor antibody could strongly inhibit tumor growth and even cause tumor regression with the glioblastoma tumor cell line, GBM18 [388236]. In May 1998, the company was granted US-05747651 by the USPTO, covering antibodies against the extracellular portion of the FLK-1/KDR receptor [284054].

• Authors: S Hunt
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 3 Issue 4 Pg. 418-24 (Aug 2001) ISSN: 1464-8431 [Print] England
• PMID: 11525567 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Receptors, Growth Factor
• Recombinant Fusion Proteins
• Receptor Protein-Tyrosine Kinases
• Receptors, Vascular Endothelial Growth Factor

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Colorectal Neoplasms (therapy)
• Humans
• Receptor Protein-Tyrosine Kinases (antagonists & inhibitors)
• Receptors, Growth Factor (antagonists & inhibitors)
• Receptors, Vascular Endothelial Growth Factor
• Recombinant Fusion Proteins (therapeutic use)